Drug Profile
Research programme: tumour imaging - GE Healthcare
Latest Information Update: 28 Mar 2006
Price :
$50
*
At a glance
- Originator GE Healthcare
- Developer Oxford BioMedica
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Mar 2006 No development reported - Preclinical for Solid tumour diagnosis in United Kingdom (unspecified route)
- 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
- 04 May 2000 Preclinical development for Solid tumour diagnosis in United Kingdom (unspecified route)